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schizophrenia in Brazil reached to US$195,885,270.68. Of this amount, only US$ 
R$7,496,366.58 (3.83%) came from states and US$188,388,904.10 (96.17%) from 
MoH resources. This value represented 11% of MoH’s annual budget for 
acquisition of high-cost medicines. Olanzapine and quetiapine accounted for 
nearly 81% of total expenses with atypical antipsychotics (US$103,763,938.18 and 
US$55,419,573.97, respectively). The others agents represented lower impacts: 
US$23,199,945.99 (ziprasidone), US$12,881,256.10 (clozapine) and US$620,556.45 
(risperidone). CONCLUSIONS: The data demonstrate the impact of financial 
resources applied in atypical antipsychotics to treat schizophrenia in SUS. In this 
scenario, strategies to strengthen the health industrial complex and to optimize 
resource allocation, as the current production of olanzapine and quetiapine in 
public pharmaceutical laboratories, are very desirable.  
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OBJECTIVES: Prescription drug monitoring programs (PDMPs) can help 
pharmacists provide appropriate care to patients taking controlled prescription 
drugs (CPDs). Study objectives were to 1) describe pharmacists’ views on 
mandating PDMP use and providing opioid addiction counseling; 2) determine 
what demographic and practice characteristics are associated with CPD-related 
continuing education (CE) hours; and 3) describe actions associated with 
dispensing CPDs. METHODS: This cross-sectional mail survey of 998 randomly 
selected Texas community pharmacists was part of a larger study to examine 
pharmacists’ intention to utilize a PDMP. Data were collected anonymously from 
2/12-4/12. Descriptive and inferential statistics were used to address the study 
objectives. RESULTS: The useable response rate was 26.2%. Pharmacists were 
more supportive of mandating PDMP use for physicians (4.1±1.2) than for 
pharmacists (3.2±1.5), (1=strongly disagree to 5=strongly agree). Male, BS degreed, 
pharmacy owners (vs. managers) and ≥50 year old pharmacists reported 
significantly (p<0.05) more CE hours related to prescription opioid abuse and 
pain management. CE was significantly correlated with pharmacists’ agreement 
to provide counseling (p=0.02). More than 45% of pharmacists were “always” 
prompted to use the PDMP when: patients paid cash (48.1%), prescription had 
mistakes (68.1%) and early refill request were made (66.3%). Prior to dispensing 
CPDs, more than 45% of pharmacists “always” consulted patient records (49.2%), 
verified prescribers DEA (48.0%) and patient identification (47.5%). Almost 40% of 
pharmacists “never” discussed buprenorphine/naloxone with patients or 
prescribers if they suspected abuse; instead 92.3% refused to fill the prescription 
and 44.0% were neutral regarding notifying law enforcement and counseling 
(35.1%). Pharmacists with a BS degree expressed higher agreement with opioid 
addiction counseling (p=0.02). CONCLUSIONS: Older male pharmacists received 
more CE and seemed more willing to provide counseling to patients with opioid 
addiction. As PDMP use becomes more prevalent, pharmacists should be 
prepared to interact and counsel patients with addictive patterns of prescription 
opioid use.  
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Carroll CA1, Lage MJ2, Velligan DI3, Fairman KA4 
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OBJECTIVES: Quantify changes in health care resource utilization and costs 
following clozapine initiation in Medicaid beneficiaries with schizophrenia or 
schizoaffective disorders. METHODS: Data were derived from the MarketScan 
Medicaid database for dates of service between 2007-2009. Patients had >1 
clozapine claim without clozapine use in the 12 months prior to the initiation 
(index) date; had >1 diagnosis of schizophrenic disorder (ICD-9-CM=295.xx) in the 
12 months prior (preperiod) through 12 months after (postperiod) index; were 
continuously enrolled throughout the preperiod and postperiod; and were aged 
18-64 years. Outcome measures included health care payments and resource 
utilization in 3 categories: all-cause (primary outcome); disease-specific (mental 
health and schizophrenia diagnoses); and cardiometabolic (cardiovascular or 
diabetes diagnoses). Comparisons of preperiod versus postperiod values were 
made using paired t-tests and McNemer’s tests for continuous and categorical 
variables, respectively. RESULTS: Mean patient age (n=1,045) was 36.32 years; 
56.1% male. Following clozapine initiation, mean 12-month all-cause health care 
payments did not change significantly (preperiod=$27,407, postperiod=$26,518, 
P=0.415). Payments for mental health and schizophrenia-related claims declined 
by 13.6% (P<0.001) and 11.7% (P=0.016), respectively. Increases in outpatient costs 
were offset by inpatient service cost reductions; significant declines were 
observed from the preperiod to the postperiod in the percentages of patients 
with hospitalizations for all causes (40.6% vs. 35.7%, P=0.003), mental disorders 
(40.2% vs. 35.1%, P<0.001), and schizophrenia (35.9% vs. 31.6%, P=0.007). No 
significant changes in cardiovascular or diabetes costs were observed. 
CONCLUSIONS: Clozapine initiation was associated with reductions in disease-
specific health care utilization and costs without increased cardiometabolic 
costs.  
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OBJECTIVES: To identify sociodemographic factors associated with off-patent 
brand antidepressants utilization. METHODS: Secondary data analysis was 
conducted using 2010 Medical Expenditure Panel Survey (MEPS). Although the 
following medications were available in generic products as of 2010: Venlafaxine, 
Fluoxetine, Paroxetine, Bupropion, Citalopram, Sertraline, Mirtazapine. 216 
unique participants were identified as brand users out of 1694 participants 
taking the aforementioned medications. Race, family’s total income, health 
insurance coverage, gender, and age were categorized and included first in 
bivariate logistic regression to identify significant predictor variables for the 
utilization of off-patent brand antidepressants. Charlson Co-morbidity Index 
(CCI) score was calculated using ICD9CODX variable and the total score was 
included in the analysis. The significant predictor variables were then included 
in multivariable logistic regression model. RESULTS: Brand users were more 
likely to be White (non-Hispanic) (OR=2.158, 95% CI=1.27-3.659), female 
(OR=1.678, 95% CI=1.109-2.537), having private insurance (OR=1.481, 95% 
CI=1.028-2.134) and from upper middle income class (family’s total income: 
$100,000-$500,000) (OR=1.595, 95% CI=1.030-2.471). However, race (White (non-
Hispanic)) and gender (female) variables were found to be significantly 
associated with brand utilization (P<0.05) after accounting for income and 
insurance coverage. Participants with zero CCI score (absence of CCI’s 17 chronic 
medical conditions) were more likely to be brand user (OR=1.286, 95% CI=0.901-
1.837) although this was not found to be statistically significant (P>0.05). 
CONCLUSIONS: Despite some case reports and bioequivalence studies 
suggesting a disadvantage in efficacy and tolerability of generic medications 
compared with brand-name equivalents, the preponderance of evidence 
suggests that generic antidepressants provide cost savings over brand-name 
medications and equal discontinuation rate. Racial as well as gender differences 
in brand antidepressants preferences were identified, which will possibly help 
clinicians counsel patients with higher likelihood of utilizing off-patent brand-
name antidepressants to help dispel any misconceptions about generic 
antidepressants’ efficacy.  
 
PMH62  
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USING DIFFERENT PUBLIC USE FILES  
Chen YJ 
IMS Health, Alexandria, VA, USA  
OBJECTIVES: The Centers for Medicare and Medicaid Services recently increased 
public access to its Medicare data with the release of Basic Stand Alone (BSA) 
Medicare Claims Public Use Files. This study sought to compare the estimates 
obtained from new BSA claims and public survey data on the number of 
prescriptions per visit associated with Alzheimer's disease (AD) among elderly 
patients in the ambulatory setting. METHODS: Visits of Medicare beneficiaries 
aged 65+ with AD (ICD-9-CM 290, 294, 331, or disease indicator variable) were 
identified in two available data years (2008 and 2010) of BSA claims and two 
national surveys (National Ambulatory Medical Care Survey [NAMCS] and 
outpatient component of National Hospital Ambulatory Medical Care Survey 
[NHAMCS]) of the same years. Descriptive statistics were compared between the 
claims and survey sources on patients’ demographics, co-morbidities, and drug 
use. Numbers of prescriptions per visit were compared between patients with 
and without AD through multivariate regressions (Generalized Linear Model with 
Poisson distribution), controlling for age, sex, and a series of co-morbidities. 
RESULTS: Ambulatory visits by Medicare-covered elderly AD patients were 
identified. As compared to the two surveys, the claims source involves more 
female beneficiaries (64.8% vs. 52.9%) and has higher proportion of patients with 
other chronic conditions in addition to AD (88.2% vs. 67.8%). The top 3 co-
morbidities in the claims source are myocardial ischaemia, heart failure and 
diabetes, while the list is different in surveys as arthritis, diabetes and cancer. 
AD contributes an increased drug use of 2.3 prescriptions per visit in claims and 
1.1 prescriptions in surveys, as predicted by multivariate regressions. 
CONCLUSIONS: This study is an initial exploration comparing the new Medicare 
claims source with national surveys on AD patients’ drug use. Further 
evaluations are needed to inform the use of this new public data source in health 
services research.  
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OBJECTIVES: Considering depression as a major public health problem 
worldwide, the aim of our study was to determine the total utilization and 
pattern of use of antidepressants in Serbia in correlation with Finland. 
METHODS: The data on utilization of antidepressant drugs (ATC group N06) 
during the four-year period (2006-2010) were retrieved by a retrospective, 
observational, population-based study. The ATC/DDD methodology was applied 
and the results were expressed in defined daily doses per 1000 inhabitants per 
day (DID). RESULTS: During the observed period of time, the overall utilization of 
antidepressants showed a modest tendency to increase in both countries (12.2% 
in Finland and 15.93% in Serbia). In 2010, overall utilization of antidepressants in 
Serbia (11,67 DID) appeared to be 6 times lower than in Finland (68.83 DID). 
Throughout the whole studied period, the selective serotonine reuptake 
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inhibitors (SSRIs) were the most commonly used subgroup of antidepressant 
drugs in both countres (63.88% and 73.76% in Finland and Serbia in 2010, 
respectively) which is in accordance with a current clinical practice guidelines. 
Eight drugs fell under DU90% segment in both observed countries, but the share 
of utilization of antidepressants differed between countries. Sertraline was the 
most commonly used in Serbia (47.73%), while citalopram and escitalopram 
accounted for the highest share in Finland (25.43% and 17.11%, respectively). 
CONCLUSIONS: The large differences in utilization of antidepressants between 
observed countries implies possible underdiagnosing of affective disorders in 
general practice. The differences are partly consequence of different 
socioeconomic and health policy factors among the selected countries. To reduce 
the serious consequences that may be caused on that way, the early diagnosis 
and timely, adequate and effective management and treatment of depression is 
essential. Acknowledgement: This work is supported by Ministry of Education 
and Science, Republic of Serbia, project No. 41012.  
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OBJECTIVES: Psychotropic drugs have been associated with an increased risk of 
falls, particularly when used by seniors. Unintentional falls are the leading cause 
of injury-related hospital admissions among seniors. This study examines the 
use of three psychotropic drug classes: benzodiazepines and related drugs, 
antidepressants and antipsychotics. METHODS: Claims level data from the 
National Prescription Drug Utilization Information System (NPDUIS) Database 
were analyzed for seniors on public drug programs in six Canadian provinces 
between 2001-2002 and 2009-2010. This analysis looked at trends in selected 
psychotropic drug use, including use by age and sex, and a comparison of use in 
community and long-term care settings. Within each class, trends in use of 
chemical subgroups were examined. RESULTS: The age–sex-standardized rate of 
selected psychotropic drug use increased slightly during the study period, from 
32.1% in 2001–2002 to 33.5% in 2009–2010. The use of antidepressants and 
antipsychotics increased, while benzodiazepine use among seniors decreased. In 
2009–2010, the rate of selected psychotropic drug use was 74.9% among nursing 
home residents, compared with 34.0% among non–nursing home residents. The 
rate of selected psychotropic drug use decreased with age among seniors in 
nursing homes but increased with age among those not in nursing homes. 
CONCLUSIONS: Further investigation of the use of these drugs in seniors is 
required, particularly among older seniors and seniors living in nursing homes, 
where rates of use are particularly high. The risks associated with these selected 
psychotropic drugs are of particular concern in seniors, who are already at 
heightened risk of adverse events due to the number of drugs they are taking, 
their higher prevalence of certain chronic conditions, and age-related changes in 
the body.  
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OBJECTIVES: Use of atypical antipsychotics for conditions such as conduct 
disorder, depression, ADHD, and Tourette’s syndrome in children is highly 
prevalent; however, efficacy has not been proven in clinical trials. A DHHS letter 
to state Medicaid directors expressed concern over the use of antipsychotics in 
children and initiated steps to increase its safe, effective and appropriate use. 
This study examined the level of evidence available in claims to support atypical 
antipsychotic use in Mississippi Medicaid children and young adults. METHODS: 
A retrospective analysis was conducted using the Mississippi Medicaid claims 
data from 2008-2011. Pharmacy and medical claims files were linked using 
beneficiary ID. Prescriptions, included only if the beneficiary was below 21 years 
of age on the day of the claim, were classified as to whether a diagnosis to 
support the use of the drug appeared in medical claims within one year of the 
prescriptions and whether diagnoses that were in the claims were supported by 
evidence ratings provided in Micromedex. RESULTS: The 7,487 beneficiaries 
eligible for the study accounted for a total of 107,544 prescriptions for 
antipsychotics. 75.6% of these prescriptions could not be associated with an 
identifiable mental illness diagnosis from the medical claims. Of the 26,164 
prescriptions that were associated with a diagnosis, about 53% of the 
prescriptions were supported by evidence. Among the other 47%, which were not 
supported by evidence, depression, bipolar disorder and mental retardation were 
the most common diagnoses. CONCLUSIONS: It appears that some antipsychotic 
use in this population may not be supported by evidence and/or prescribers are 
reluctant to record mental health diagnoses. Since most of these prescriptions 
required prior authorization, diagnoses were provided but do not appear in the 
medical claims. The lack of supporting diagnoses in medical claims is a 
significant limitation when examining the use of antipsychotics among children.  
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OBJECTIVES: There is a dearth of real-world information on preschoolers with 
attention-deficit/hyperactivity disorder (ADHD) and few ADHD medications are 
approved for children under age 6. This study sought to identify characteristics 
and treatment patterns of preschoolers with ADHD, compare preschoolers to 
older children, and assess conformity with preschooler treatment guidelines 
which recommend behavioral interventions prior to pharmacotherapy. 
METHODS: Medicaid beneficiaries with an ADHD diagnosis (ICD-9 314.0x) in 
2010, continuous enrollment 12 months pre/post the earliest diagnosis (‘index’), 
and a confirmatory diagnosis were identified in the Truven Health MarketScan® 
Multi-State Medicaid Database. Preschool (age 4-5), school-age (6-11), and 
adolescent (12-18) cohorts were based on age at index. Age cohorts were 
compared on patient characteristics, behavioral health services, and prescription 
drug claims using MarketScan Treatment Pathways. RESULTS: The sample 
(10,347 preschoolers; 70,101 school-age children; 43,347 adolescents) was 
predominantly male. Significantly (p<0.001) more preschoolers had learning 
disabilities and hearing disorders (16%, 12%) than school-age children (12%, 6%) 
and adolescents (5%, 4%). Depression and anxiety rates increased significantly 
with age from 4% and 6% in preschoolers to 18% and 10% in adolescents. 
Methylphenidate and amphetamine salt combinations were the main ADHD 
medications across all cohorts, but preschoolers were less likely to receive long-
acting formulations. Dextroamphetamine, clonidine, and guanfacine utilization 
was higher in preschoolers; atomoxetine and lisdexamphetamine utilization was 
higher in older children. Within 30 days of diagnosis, 54% of newly-diagnosed 
preschoolers filled an ADHD medication prescription versus 62% school-aged 
children and 58% adolescents (p<0.001). Corresponding behavioral health 
services rates were 29%, 26% and 34% (p<0.001). CONCLUSIONS: Most children 
with ADHD are treated with medication; predominant medications differ by age 
group. In contrast to treatment guidelines suggesting preschoolers try behavioral 
interventions before medication, over half of newly-diagnosed preschoolers 
filled ADHD prescriptions within a month of diagnosis but less than a third 
incurred behavioral health services.  
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OBJECTIVES: Antipsychotic medications are the primary pharmacologic 
treatment for schizophrenia. This study characterized the outpatient medication 
treatment patterns for schizophrenia from 2003-2010 in the United States. 
METHODS: Data from the National Ambulatory Care Survey (NAMCS) and the 
National Hospital Ambulatory Medical Care Survey (NHAMCS) for 2003-2010 were 
pooled and weighted to provide national level estimates. Schizophrenia was 
identified using the ICD-9 code 295.xx. The data contained information on 3,211 
visits for schizophrenia, representing 22.3 million outpatient visits in the United 
States during 2003-2010. Using procedures that reflected the multistage sampling 
of the surveys, representative estimates were made for patient and physician 
characteristics, payer type, and medication use patterns. RESULTS: Most 
schizophrenia visits were covered by Medicare (35.7% [31.2%-40.4%]) and 
Medicaid (35.2% [31.4%-39.2%]) rather than private insurance (13.1% [10.5%-
16.1%). Antipsychotics were prescribed at most visits (78.8% [75.1%-82.1%]), 
including antipsychotic polypharmacy at 21.5% [18.4%-25.1%] of visits, second-
generation antipsychotic (SGA) monotherapy at 45.3% [41.5%-49.2%] of the visits, 
and first-generation antipsychotic (FGA) monotherapy at 11.9% [9.6%-14.7%] of 
visits. The most commonly used antipsychotics were risperidone (25.1% [21.8%-
28.7%]), olanzapine (22.7% [19.7%-26.0%]), and quetiapine (16.5% [12.8%-20.9%]). 
Quetiapine was most strongly associated with antipsychotic polypharmacy 
(55.4% [44.8%-65.6%]) and concomitant use of anticonvulsants (38.0% [25.7%-
52.1%]), sedatives (44.5% [32.5%-57.2%]), and antidepressants (55.5% [42.6%-
67.7%]). Risperidone (23.2% [16.7%-31.2%]) and FGAs (35.8% [29.6%-42.6%]) were 
associated with highest rates of anticholinergic use. Rates of polypharmacy, FGA 
monotherapy, and SGA monotherapy did not change significantly across the 
study period (p = 0.396). CONCLUSIONS: Meaningful differences exist between 
outpatient visits for different antipsychotics in terms of antipsychotic 
polypharmacy, concomitant psychotropic, and non-psychotropic medications. 
This analysis demonstrates the utility of the NAMCS and NHAMCS data for 
investigating disease states and their treatment patterns.  
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OBJECTIVES: To examine the difficulty using services reported by caregivers of 
children aged 3-17 years with ASD as compared to caregivers of children with 
other developmental disorders (DD) and mental health conditions (MHC). 
METHODS: A cross sectional study was conducted using the 2009-2010 National 
Survey of Children with Special Health Care Needs (NS-CSHCN) (N = 18,702). 
Difficulty using services was assessed as issues with: eligibility, availability, 
getting appointments, cost, and obtaining information. Chi-square analyses and 
separate binomial logistic regressions were conducted to compare likelihood of 
difficulty with all five measures across ASD, DD only, MHC only, and DD & MHC 
groups, after adjusting for socio-demographics, number of special children in the 
household, child’s functional ability, and presence of a physical condition. 
RESULTS: Majority of the sample were older children (6-17 years), Whites, 
caregivers with ≥200% FPL income and greater than high school education. 
